Sun Pharmaceuticals Industries announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 21 January 2025.Powered by Capital Market - Live News

Net profit of Sun Pharmaceuticals Industries rose 27.98% to Rs 3040.16 crore in the quarter ended September 2024 as against Rs 2375.51 crore during the previous quarter ended September 2023. Sales rose 10.51% to Rs 13264.22 crore in the quarter ended September 2024 as against Rs 12003.11 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales13264.2212003.11 11 OPM %29.7026.49 - PBDT4223.793423.70 23 PBT3597.882790.88 29 NP3040.162375.51 28 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 28 October 2024Powered by Capital Market - Live News

Sun Pharmaceutical Industries and Philogen S.p.A (Philogen) today announced that they have entered into a global licensing agreement for commercializing Philogen`s specialty product, Fibromun (L19TNF). Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun. Philogen will complete the ongoing pivotal clinical trials for the product, pursue Marketing Authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio. Other financial terms were not disclosed. Powered by Capital Market - Live News

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway. The FDA`s Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review. �As we enter Phase 3 development, we are very encouraged by the FDA`s decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis,� said Marek Honczarenko, MD, PHD, Senior Vice President, Head Global Development at Sun Pharma.Powered by Capital Market - Live News